Vericel Co. (NASDAQ:VCEL) Shares Purchased by MML Investors Services LLC

MML Investors Services LLC grew its holdings in shares of Vericel Co. (NASDAQ:VCEL) by 26.7% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 7,125 shares of the biotechnology company’s stock after buying an additional 1,501 shares during the period. MML Investors Services LLC’s holdings in Vericel were worth $301,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also modified their holdings of the business. International Assets Investment Management LLC boosted its stake in shares of Vericel by 4,126.7% in the third quarter. International Assets Investment Management LLC now owns 634 shares of the biotechnology company’s stock valued at $27,000 after buying an additional 619 shares in the last quarter. Farther Finance Advisors LLC grew its stake in shares of Vericel by 48.1% during the 3rd quarter. Farther Finance Advisors LLC now owns 1,247 shares of the biotechnology company’s stock worth $53,000 after purchasing an additional 405 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Vericel by 22.2% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,773 shares of the biotechnology company’s stock valued at $77,000 after purchasing an additional 322 shares in the last quarter. Meeder Asset Management Inc. acquired a new stake in shares of Vericel in the third quarter valued at about $92,000. Finally, Quantbot Technologies LP purchased a new stake in Vericel during the third quarter worth about $146,000.

Insider Buying and Selling

In other news, CEO Dominick Colangelo sold 17,500 shares of the firm’s stock in a transaction dated Wednesday, October 16th. The stock was sold at an average price of $41.38, for a total value of $724,150.00. Following the transaction, the chief executive officer now directly owns 220,937 shares in the company, valued at $9,142,373.06. This trade represents a 7.34 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Paul K. Wotton sold 2,600 shares of Vericel stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $58.72, for a total value of $152,672.00. Following the completion of the transaction, the director now directly owns 27,402 shares in the company, valued at $1,609,045.44. This represents a 8.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 44,266 shares of company stock valued at $2,090,636. Insiders own 5.20% of the company’s stock.

Vericel Stock Up 0.5 %

Shares of Vericel stock opened at $57.31 on Thursday. Vericel Co. has a fifty-two week low of $32.31 and a fifty-two week high of $61.49. The business’s fifty day moving average is $52.35 and its two-hundred day moving average is $48.44. The firm has a market cap of $2.83 billion, a PE ratio of 955.33 and a beta of 1.70.

Vericel (NASDAQ:VCEL) last released its earnings results on Thursday, November 7th. The biotechnology company reported ($0.02) earnings per share for the quarter, topping the consensus estimate of ($0.05) by $0.03. The firm had revenue of $57.91 million for the quarter, compared to the consensus estimate of $55.32 million. Vericel had a return on equity of 1.48% and a net margin of 1.56%. Equities research analysts anticipate that Vericel Co. will post 0.13 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts have recently commented on VCEL shares. HC Wainwright reissued a “buy” rating and set a $60.00 price target on shares of Vericel in a research note on Friday, November 8th. Truist Financial raised their price target on Vericel from $61.00 to $67.00 and gave the company a “buy” rating in a research report on Wednesday, December 18th. BTIG Research increased their price objective on shares of Vericel from $56.00 to $66.00 and gave the company a “buy” rating in a research note on Tuesday, November 26th. Stephens raised shares of Vericel to a “strong-buy” rating in a report on Monday, December 2nd. Finally, Canaccord Genuity Group reissued a “buy” rating and set a $60.00 price objective on shares of Vericel in a research note on Tuesday, November 19th. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $61.14.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.